Fulgent Genetics Stock Performance

FLGT Stock  USD 23.44  0.27  1.14%   
The firm shows a Beta (market volatility) of 0.0334, which means not very significant fluctuations relative to the market. As returns on the market increase, Fulgent Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fulgent Genetics is expected to be smaller as well. At this point, Fulgent Genetics has a negative expected return of -0.34%. Please make sure to confirm Fulgent Genetics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Fulgent Genetics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Fulgent Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more

Actual Historical Performance (%)

One Day Return
(2.09)
Five Day Return
(11.97)
Year To Date Return
(10.32)
Ten Year Return
150
All Time Return
150
1
Piper Sandler Issues Positive Forecast for Fulgent Genetics Stock Price
11/11/2025
2
Disposition of 671 shares by Paul Kim of Fulgent Genetics at 30.0 subject to Rule 16b-3
11/21/2025
3
Fulgent Genetics Reaches New 1-Year High - Heres Why - MarketBeat
11/25/2025
4
Disposition of 2944 shares by Ming Hsieh of Fulgent Genetics at 30.15 subject to Rule 16b-3
11/26/2025
5
Disposition of 943 shares by Gao Hanlin of Fulgent Genetics at 29.5695 subject to Rule 16b-3
11/28/2025
6
Disposition of 1131 shares by Paul Kim of Fulgent Genetics at 28.52 subject to Rule 16b-3
12/01/2025
7
Disposition of 1075 shares by Gao Hanlin of Fulgent Genetics at 28.3318 subject to Rule 16b-3
12/02/2025
8
Jian Xie Sells 1,140 Shares of Fulgent Genetics Stock - MarketBeat
12/04/2025
9
Fulgent Genetics Cut to Hold at Wall Street Zen
12/16/2025
10
FLGT to Acquire Bako StrataDx Assets to Expand Pathology Platform
12/23/2025
11
Disposition of 8031 shares by Jian Xie of Fulgent Genetics at 16.29 subject to Rule 16b-3
01/06/2026
12
Fulgent Genetics Stock Price Up 7.3 percent - Time to Buy - MarketBeat
01/07/2026
13
Buyout Rumor Why Fulgent Genetics Inc stock remains undervalued - Watch List Fast Entry and Exit Trade Plans - moha.gov.vn
01/13/2026
14
Disposition of 1556 shares by Paul Kim of Fulgent Genetics at 15.45 subject to Rule 16b-3
01/22/2026
15
Disposition of 985 shares by Gao Hanlin of Fulgent Genetics at 15.45 subject to Rule 16b-3
01/23/2026
16
Disposition of 3004 shares by Paul Kim of Fulgent Genetics at 27.53 subject to Rule 16b-3
01/26/2026
17
Disposition of 2951 shares by Jian Xie of Fulgent Genetics at 16.29 subject to Rule 16b-3
02/02/2026
Begin Period Cash Flow97.5 M
Total Cashflows From Investing Activities-58.4 M

Fulgent Genetics Relative Risk vs. Return Landscape

If you would invest  2,908  in Fulgent Genetics on November 12, 2025 and sell it today you would lose (564.00) from holding Fulgent Genetics or give up 19.39% of portfolio value over 90 days. Fulgent Genetics is currently does not generate positive expected returns and assumes 1.9758% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Fulgent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Fulgent Genetics is expected to under-perform the market. In addition to that, the company is 2.44 times more volatile than its market benchmark. It trades about -0.17 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of volatility.

Fulgent Genetics Target Price Odds to finish over Current Price

The tendency of Fulgent Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 23.44 90 days 23.44 
about 98.0
Based on a normal probability distribution, the odds of Fulgent Genetics to move above the current price in 90 days from now is about 98.0 (This Fulgent Genetics probability density function shows the probability of Fulgent Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Fulgent Genetics has a beta of 0.0334. This usually indicates as returns on the market go up, Fulgent Genetics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Fulgent Genetics will be expected to be much smaller as well. Additionally Fulgent Genetics has an alpha of 0.0518, implying that it can generate a 0.0518 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Fulgent Genetics Price Density   
       Price  

Predictive Modules for Fulgent Genetics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fulgent Genetics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
21.5123.4925.47
Details
Intrinsic
Valuation
LowRealHigh
21.1028.0930.07
Details
3 Analysts
Consensus
LowTargetHigh
30.6433.6737.37
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.19-0.11-0.02
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Fulgent Genetics. Your research has to be compared to or analyzed against Fulgent Genetics' peers to derive any actionable benefits. When done correctly, Fulgent Genetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Fulgent Genetics.

Fulgent Genetics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Fulgent Genetics is not an exception. The market had few large corrections towards the Fulgent Genetics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fulgent Genetics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fulgent Genetics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.05
β
Beta against Dow Jones0.03
σ
Overall volatility
1.81
Ir
Information ratio -0.01

Fulgent Genetics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fulgent Genetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fulgent Genetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Fulgent Genetics generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 130.14 M.
About 56.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Disposition of 2951 shares by Jian Xie of Fulgent Genetics at 16.29 subject to Rule 16b-3

Fulgent Genetics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fulgent Stock often depends not only on the future outlook of the current and potential Fulgent Genetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulgent Genetics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding30.2 M
Cash And Short Term Investments258.1 M

Fulgent Genetics Fundamentals Growth

Fulgent Stock prices reflect investors' perceptions of the future prospects and financial health of Fulgent Genetics, and Fulgent Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulgent Stock performance.

About Fulgent Genetics Performance

Assessing Fulgent Genetics' fundamental ratios provides investors with valuable insights into Fulgent Genetics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Fulgent Genetics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 19.97  24.94 
Return On Tangible Assets(0.04)(0.04)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.03)(0.03)
Return On Equity(0.03)(0.04)

Things to note about Fulgent Genetics performance evaluation

Checking the ongoing alerts about Fulgent Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulgent Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Fulgent Genetics generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 130.14 M.
About 56.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Disposition of 2951 shares by Jian Xie of Fulgent Genetics at 16.29 subject to Rule 16b-3
Evaluating Fulgent Genetics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Fulgent Genetics' stock performance include:
  • Analyzing Fulgent Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulgent Genetics' stock is overvalued or undervalued compared to its peers.
  • Examining Fulgent Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Fulgent Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulgent Genetics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Fulgent Genetics' stock. These opinions can provide insight into Fulgent Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Fulgent Genetics' stock performance is not an exact science, and many factors can impact Fulgent Genetics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.